Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $22 t...
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improveme...
Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial Exe...
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continue...
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continue...
Chardan Capital analyst Rudy Li maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $24 price target.
